Mochida Pharmaceutical

Company snapshot

Mochida Pharmaceutical Company is a pharma organization headquartered in CN. Primary therapeutic focus areas include Hypertriglyceridemia. NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (2), phase 1 (1).

• 3 active pipeline program(s) linked via ClinicalTrials.gov.
• 3 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Mochida Pharmaceutical. Not investment advice.

• What is Mochida Pharmaceutical?

  Mochida Pharmaceutical Company is a pharma organization headquartered in CN. Primary therapeutic focus areas include Hypertriglyceridemia. NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov

• Is Mochida Pharmaceutical publicly traded?

  Mochida Pharmaceutical appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Mochida Pharmaceutical develop or market?

  We link 2 drug profile(s) where Mochida Pharmaceutical is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/mochida-pharmaceutical-company#company-drugs.

• What are the latest developments for Mochida Pharmaceutical?

  In the last 12 months our linked public records show 3 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Mochida Pharmaceutical focus on?

  Mochida Pharmaceutical focuses on Hypertriglyceridemia based on our analysis of their pipeline programs and drug development activities.